SECURITIES PURCHASE AGREEMENT Dated May 15, 2015 by and between HEDGEPATH PHARMACEUTICALS, INC. and MAYNE PHARMA VENTURES PTY LTDSecurities Purchase Agreement • August 14th, 2015 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research • Delaware
THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into this 15th day of May, 2015 (the “Signing Date”), by and between MAYNE PHARMA VENTURES PTY LTD, an Australian company ACN 168 896 357 (“Mayne Pharma”) and HEDGEPATH PHARMACEUTICALS, INC., a Delaware corporation (“HPPI”).
FOIA CONFIDENTIAL TREATMENT REQUEST BY HEDGEPATH PHARMACEUTICALS, INC. IRS EMPLOYER IDENTIFICATION NUMBER 30-0793665Supply and License Agreement • August 14th, 2015 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research • Delaware
HEDGEPATH PHARMACEUTICALS, INC. AMENDED AND RESTATED EQUITY HOLDERS’ AGREEMENT Dated As of May 15, 2015Equity Holders' Agreement • August 14th, 2015 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research • Delaware
This AMENDED AND RESTATED EQUITY HOLDERS’ AGREEMENT (this “Agreement”) is made and entered into as of the 15th day of May, 2015 (the “Effective Date”) by and among:
FIRST AMENDMENT TO EXECUTIVE CHAIRMAN AGREEMENTExecutive Chairman Agreement • August 14th, 2015 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research • Delaware
THIS FIRST AMENDMENT TO EXECUTIVE CHAIRMAN AGREEMENT (the “Amendment”), is dated as of May 15, 2015, by and between HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Frank E. O’Donnell, Jr., M.D. (the “Executive Chairman”). The Company and the Executive Chairman are referred to collectively herein as the “Parties.”
FOIA CONFIDENTIAL TREATMENT REQUEST BY HEDGEPATH PHARMACEUTICALS, INC. IRS EMPLOYER IDENTIFICATION NUMBER 30-0793665Master Clinical Services Agreement • August 14th, 2015 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research • California
This Master Clinical Services Agreement (this “Agreement”) is executed as of 15 June, 2015 and made effective as of 29 September, 2014 (“Effective Date”), by and between SciQuus, Inc., a Delaware corporation, having a place of business at 4250 Executive Square, Suite 450, La Jolla, CA 92037 (hereinafter “SciQuus”), and HedgePath Pharmaceuticals, Inc., a Delaware corporation having a place of business at 324 S. Hyde Park Avenue, Ste. 350 Tampa, Florida 33606 (hereinafter “Sponsor”). Sponsor and SciQuus are sometimes referred to herein individually as a “Party” and together as the “Parties.”
FIRST AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • August 14th, 2015 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research
THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (the “Amendment”), is dated as of May 15, 2015 by and between HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Nicholas J. Virca (the “Executive”). The Company and the Executive are referred to collectively herein as the “Parties.”
